Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 1
Submit an article Journal homepage
810
Views
35
CrossRef citations to date
0
Altmetric
Review

Traceability of biologicals: present challenges in pharmacovigilance

Niels S VermeerUtrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Universiteitsweg 99, Utrecht, 3584CG, The Netherlands+31 302537324; +31 302539166; [email protected];Medicines Evaluation Board, Utrecht, The Netherlands
, MSc,
Irina SpieringsUtrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Universiteitsweg 99, Utrecht, 3584CG, The Netherlands+31 302537324; +31 302539166; [email protected]
, BSc,
Aukje K Mantel-TeeuwisseUtrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Universiteitsweg 99, Utrecht, 3584CG, The Netherlands+31 302537324; +31 302539166; [email protected]
, PhD,
Sabine MJM StrausMedicines Evaluation Board, Utrecht, The Netherlands;Erasmus Medical Center, Department of Medical Informatics, Rotterdam, The Netherlands
, PhD,
Thijs J GiezenPharmacy Foundation of Haarlem Hospitals, Haarlem, The Netherlands
, PhD,
Hubert GM LeufkensUtrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Universiteitsweg 99, Utrecht, 3584CG, The Netherlands+31 302537324; +31 302539166; [email protected];Medicines Evaluation Board, Utrecht, The Netherlands
, PhD,
Toine CG EgbertsUtrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Universiteitsweg 99, Utrecht, 3584CG, The Netherlands+31 302537324; +31 302539166; [email protected];University Medical Center Utrecht, Department of Clinical Pharmacy, Utrecht, The Netherlands
, PhD &
Marie L De BruinUtrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Universiteitsweg 99, Utrecht, 3584CG, The Netherlands+31 302537324; +31 302539166; [email protected];Medicines Evaluation Board, Utrecht, The Netherlands
, PhD show all
Pages 63-72 | Published online: 05 Nov 2014

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Julia Schmälter. (2019) A street-level perspective on non-compliance in the EU: new lessons to draw?. Journal of Contemporary European Studies 27:1, pages 1-14.
Read now
Morton Scheinberg, Carlos Pineda, Gilberto Castañeda-Hernández, Juan José Zarbá, Aderson Damião, Luiz H Arantes Jr & Ira Jacobs. (2018) Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America. mAbs 10:6, pages 827-842.
Read now
Shashidhar Swamy, Meenakshi Mourya, Ganesh Kadhe, Amey Mane & Sandesh Sawant. (2015) Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective. Expert Opinion on Drug Safety 14:9, pages 1409-1420.
Read now

Articles from other publishers (32)

Shannan Liu, Ronghua Zhang, Changzheng Liu & Du Shi. (2023) P-PBFT: An improved blockchain algorithm to support large-scale pharmaceutical traceability. Computers in Biology and Medicine 154, pages 106590.
Crossref
Dragica Edrovska, Aleksandra Grozdanova, Katerina Ancevska Netkovska & Zorica Naumovska. (2022) Traceability of biologicals: challenges in pharmacovigilance. Macedonian Pharmaceutical Bulletin 68:03, pages 481-482.
Crossref
Luis Correia Pinheiro, Thijs J. Giezen, Elena Wolff‐Holz, Martina Weise, Andrea Laslop & Ana Hidalgo‐Simon. (2021) Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions. Clinical Pharmacology & Therapeutics 110:5, pages 1311-1317.
Crossref
Catherine A. Panozzo, Kevin Huang & Christine Y. Lu. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters 177 194 .
Kevin Klein, Lorna Hazell, Pieter Stolk & Saad Shakir. (2019) The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK. Drug Safety 43:3, pages 255-263.
Crossref
Babak Soleimani, Katy Murray & David Hunt. (2019) Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. Drug Safety 42:8, pages 941-956.
Crossref
S. C. Kowalski, J. A. Benavides, P. A. B. Roa, C. Galarza-Maldonado, C. V. Caballero-Uribe, E. R. Soriano, C. Pineda, V. F. Azevedo, G. Avila-Pedretti, A. M. Babini, A. Cachafeiro-Vilar, M. Cifuentes-Alvarado, S. B. Cohen, P. E. Díaz, L. Diaz Soto, C. Encalada, B. Garro, I. A. G. Sariego, M. Guibert-Toledano, V. J. K. Rodriguez, M. E. L. Lopez, A. P. Ortega, A. S. Russell, P. Santos-Moreno, I. S. Terán, A. Vargas, G. Vásquez, R. M. Xavier, D. X. Xibillé Firedman, E. Mysler & J. Kay. (2019) PANLAR consensus statement on biosimilars. Clinical Rheumatology 38:5, pages 1485-1496.
Crossref
Niels S. Vermeer, Thijs J. Giezen, Sofia Zastavnik, Elena Wolff‐Holz & Ana Hidalgo‐Simon. (2019) Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice. Clinical Pharmacology & Therapeutics 105:4, pages 962-969.
Crossref
Gianluca Trifirò, Rosa Gini, Francesco Barone-Adesi, Ettore Beghi, Anna Cantarutti, Annalisa Capuano, Carla Carnovale, Antonio Clavenna, Mirosa Dellagiovanna, Carmen Ferrajolo, Matteo Franchi, Ylenia Ingrasciotta, Ursula Kirchmayer, Francesco Lapi, Roberto Leone, Olivia Leoni, Ersilia Lucenteforte, Ugo Moretti, Alessandro Mugelli, Luigi Naldi, Elisabetta Poluzzi, Concita Rafaniello, Federico Rea, Janet Sultana, Mauro Tettamanti, Giuseppe Traversa, Alfredo Vannacci, Lorenzo Mantovani & Giovanni Corrao. (2018) The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. Drug Safety 42:3, pages 347-363.
Crossref
Ylenia Ingrasciotta, Paola M. Cutroneo, Ilaria Marcianò, Thijs Giezen, Fabiola Atzeni & Gianluca Trifirò. (2018) Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Drug Safety 41:11, pages 1013-1022.
Crossref
Sara Francescon, Giulia Fornasier & Paolo Baldo. (2018) EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies. International Journal of Clinical Pharmacy 40:4, pages 778-782.
Crossref
Reyes Gámez-Belmonte, Cristina Hernández-Chirlaque, María Arredondo-Amador, Carlos J. Aranda, Raquel González, Olga Martínez-Augustin & Fermín Sánchez de Medina. (2018) Biosimilars: Concepts and controversies. Pharmacological Research 133, pages 251-264.
Crossref
Oscar O Agoro, Sarah W Kibira, Jenny V Freeman & Hamish S F Fraser. (2018) Barriers to the success of an electronic pharmacovigilance reporting system in Kenya: an evaluation three years post implementation. Journal of the American Medical Informatics Association 25:6, pages 627-634.
Crossref
J. O’Callaghan, B. T. Griffin, J. M. Morris & Margaret Bermingham. (2018) Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. BioDrugs 32:3, pages 267-280.
Crossref
Corrado Blandizzi, Mauro Galeazzi & Guido Valesini. (2018) Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges. Pharmacological Research 128, pages 306-314.
Crossref
A.D. Cohen, J.J. WuL. Puig, S. Chimenti, R. Vender, M. Rajagopalan, R. Romiti, C. de la Cruz, L. Skov, C. Zachariae, H.S. Young, P. Foley, J.M. van der Walt, L. Naldi, E.P. Prens & A. Blauvelt. (2017) Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology 177:6, pages 1495-1502.
Crossref
Valderilio Azevedo, Thomas Dörner, Robert Strohal, John Isaacs, Gilberto Castañeda-Hernández, João Gonçalves & Iain McInnes. (2017) Biosimilars: considerations for clinical practice. Considerations in Medicine 1:1, pages 13-18.
Crossref
José M. Serra López-Matencio, Alberto Morell Baladrón & Santos Castañeda. (2017) Fármacos biosimilares: un nuevo escenario en las terapias biológicas. Reumatología Clínica 13:5, pages 287-293.
Crossref
Till Uhlig & Guro L. Goll. (2017) Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology 56:suppl_4, pages iv49-iv62.
Crossref
Joan O'Callaghan, Margaret Bermingham, Maurice Leonard, Frank Hallinan, J. Michael Morris, Una Moore & Brendan T. Griffin. (2017) Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland. Regulatory Toxicology and Pharmacology 88, pages 252-261.
Crossref
Michael Kaeding, Julia Schmälter & Christoph KlikaMichael Kaeding, Julia Schmälter & Christoph Klika. 2017. Pharmacovigilance in the European Union. Pharmacovigilance in the European Union 103 114 .
Michael Kaeding, Julia Schmälter & Christoph KlikaMichael Kaeding, Julia Schmälter & Christoph Klika. 2017. Pharmacovigilance in the European Union. Pharmacovigilance in the European Union 1 10 .
Stella Stergiopoulos, Carrie A. Brown, Thomas Felix, Gustavo Grampp & Kenneth A. Getz. (2016) A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals. Drug Safety 39:11, pages 1117-1127.
Crossref
Ilaria Marcianò, Ylenia Ingrasciotta, Francesco Giorgianni, Jenny Bolcato, Alessandro Chinellato, Roberta Pirolo, Annalisa Di Giorgio, Sonia Manna, Valentina Ientile, Rosa Gini, Mariacarmela Santarpia, Armando A. Genazzani, Ilaria Uomo, Maurizio Pastorello, Sebastiano W. Pollina Addario, Salvatore Scondotto, Pasquale Cananzi, Roberto Da Cas, Giuseppe Traversa, Mariangela Rossi, Laura Sottosanti, Achille P. Caputi & Gianluca Trifirò. (2016) How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014. BioDrugs 30:4, pages 295-306.
Crossref
Evelien Moorkens, Clara Jonker-Exler, Isabelle Huys, Paul Declerck, Steven Simoens & Arnold G. Vulto. (2016) Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. Frontiers in Pharmacology 7.
Crossref
Hans C. Ebbers, Nina Fuentes de Tienda, Marcel C. Hoefnagel, Ria Nibbeling & Aukje K. Mantel-Teeuwisse. (2016) Characteristics of product recalls of biopharmaceuticals and small-molecule drugs in the USA. Drug Discovery Today 21:4, pages 536-539.
Crossref
Niels S. Vermeer, Hans C. Ebbers, Sabine M. J. M. Straus, Hubert G. M. Leufkens, Toine C. G. Egberts & Marie L. De Bruin. (2016) The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study. Pharmacoepidemiology and Drug Safety 25:3, pages 297-306.
Crossref
Kevin Klein, Joep H. G. Scholl, Niels S. Vermeer, André W. Broekmans, Eugène P. Van Puijenbroek, Marie L. De Bruin & Pieter Stolk. (2015) Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports. Drug Safety 39:2, pages 185-192.
Crossref
Stella Stergiopoulos, Carrie A. Brown, Gustavo Grampp, Thomas Felix & Kenneth A. Getz. (2015) Identifying and Quantifying the Accuracy of Product Name Attribution of US-Sourced Adverse Event Reports in MedWatch of Somatropins and Insulins. Therapeutic Innovation & Regulatory Science 49:5, pages 706-716.
Crossref
Stella Stergiopoulos & Kenneth Getz. (2015) Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices. Drug Safety 38:8, pages 687-692.
Crossref
Ylenia Ingrasciotta, Francesco Giorgianni, Jenny Bolcato, Alessandro Chinellato, Roberta Pirolo, Daniele Ugo Tari, Chiara Troncone, Andrea Fontana, Valentina Ientile, Rosa Gini, Domenico Santoro, Mariacarmela Santarpia, Armando Genazzani, Ilaria Uomo, Maurizio Pastorello, Walter Sebastiano Pollina Addario, Salvatore Scondotto, Pasquale Cananzi, Achille Patrizio Caputi & Gianluca Trifirò. (2015) How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013. BioDrugs 29:4, pages 275-284.
Crossref
Giovanni Polimeni, Gianluca Trifirò, Ylenia Ingrasciotta & Achille P. Caputi. (2015) The advent of biosimilars for the treatment of diabetes: current status and future directions. Acta Diabetologica 52:3, pages 423-431.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.